ALK and neoplasm: Thus, NanoVelcro may be a surrogate to screen ALK positive patients eligible for ALK-targeted treatment, and CTCs captured by such technique and further FISH may resolve the problem of monitoring the genomic profiling of tumor, which may predict the treatment efficacy of Crizotinib and is hard to be achieved by traditionally tumor biopsy analysis.